![Tristan Richard Gordon Sillars](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tristan Richard Gordon Sillars
Director de Operaciones en Arquer Diagnostics Ltd. .
Perfil
Tristan Richard Gordon Sillars is currently the Chief Operating Officer & Director at Arquer Diagnostics Ltd.
He previously worked as an Associate at KPMG Transaction Services Group.
Cargos activos de Tristan Richard Gordon Sillars
Empresas | Cargo | Inicio |
---|---|---|
Arquer Diagnostics Ltd.
![]() Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Director de Operaciones | - |
Antiguos cargos conocidos de Tristan Richard Gordon Sillars.
Empresas | Cargo | Fin |
---|---|---|
KPMG Transaction Services Group | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Arquer Diagnostics Ltd.
![]() Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Health Services |
KPMG Transaction Services Group |
- Bolsa de valores
- Insiders
- Tristan Richard Gordon Sillars